Technical Analysis for INKT - MiNK Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| MACD Bearish Centerline Cross | Bearish | 0.00% | |
| Stochastic Reached Oversold | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| MACD Bearish Signal Line Cross | Bearish | 2.61% | |
| NR7 | Range Contraction | 2.61% | |
| Gapped Up | Strength | 2.61% | |
| Fell Below 20 DMA | Bearish | 1.42% | |
| Fell Below 50 DMA | Bearish | 1.42% | |
| Inside Day | Range Contraction | 1.42% |
| Alert | Time |
|---|---|
| Up 3% | about 19 hours ago |
| Fell Below Previous Day's Low | about 19 hours ago |
| Down 1% | about 19 hours ago |
| Up 2% | about 19 hours ago |
| Up 1% | about 19 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 08/08/2024
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate includes AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Cancer Life Sciences Biology Immunology Pharmacy Stem Cell Cell Therapy T Cells Immune Mediated Diseases Natural Killer T Cell Lineage Cell Therapeutics
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Cancer Life Sciences Biology Immunology Pharmacy Stem Cell Cell Therapy T Cells Immune Mediated Diseases Natural Killer T Cell Lineage Cell Therapeutics
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 1.9 |
| 52 Week Low | 0.57 |
| Average Volume | 38,104 |
| 200-Day Moving Average | 0.88 |
| 50-Day Moving Average | 0.73 |
| 20-Day Moving Average | 0.73 |
| 10-Day Moving Average | 0.74 |
| Average True Range | 0.05 |
| RSI (14) | 45.05 |
| ADX | 17.52 |
| +DI | 9.45 |
| -DI | 17.85 |
| Chandelier Exit (Long, 3 ATRs) | 0.66 |
| Chandelier Exit (Short, 3 ATRs) | 0.81 |
| Upper Bollinger Bands | 0.78 |
| Lower Bollinger Band | 0.68 |
| Percent B (%b) | 0.24 |
| BandWidth | 14.37 |
| MACD Line | 0.00 |
| MACD Signal Line | 0.00 |
| MACD Histogram | -0.0044 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.78 | ||||
| Resistance 3 (R3) | 0.77 | 0.74 | 0.77 | ||
| Resistance 2 (R2) | 0.74 | 0.73 | 0.75 | 0.76 | |
| Resistance 1 (R1) | 0.72 | 0.71 | 0.73 | 0.73 | 0.76 |
| Pivot Point | 0.70 | 0.70 | 0.70 | 0.70 | 0.70 |
| Support 1 (S1) | 0.68 | 0.68 | 0.69 | 0.68 | 0.65 |
| Support 2 (S2) | 0.65 | 0.67 | 0.65 | 0.65 | |
| Support 3 (S3) | 0.63 | 0.65 | 0.64 | ||
| Support 4 (S4) | 0.63 |
